Atherosclerosis
Volume 185, Issue 2 , Pages 271-277 , April 2006

Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population

  • P. Wanby

      Affiliations

    • Department of Internal Medicine, County Hospital of Kalmar, SE-391 85 Kalmar, Sweden
    • Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 480 448204; fax +46 480 81998.
    • ,
  • T. Teerlink

      Affiliations

    • Department of Clinical Chemistry, VU University Medical Center, Amsterdam, Netherlands
    • ,
  • L. Brudin

      Affiliations

    • Department of Clinical Physiology, County Hospital of Kalmar, Sweden
    • ,
  • L. Brattström

      Affiliations

    • Department of Internal Medicine, County Hospital of Kalmar, SE-391 85 Kalmar, Sweden
    • Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    • ,
  • I. Nilsson

      Affiliations

    • Department of Clinical Chemistry, County Hospital of Kalmar, SE-391 85 Kalmar, Sweden
    • ,
  • P. Palmqvist

      Affiliations

    • Department of Internal Medicine, County Hospital of Kalmar, SE-391 85 Kalmar, Sweden
    • Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    • ,
  • M. Carlsson

      Affiliations

    • Department of Internal Medicine, County Hospital of Kalmar, SE-391 85 Kalmar, Sweden
    • Faculty of Health Sciences, Linkoping University, Linkoping, Sweden
    • Department of Clinical Chemistry, County Hospital of Kalmar, SE-391 85 Kalmar, Sweden
    • Corresponding Author InformationCorresponding author. Tel.: +46 480 81456; fax: +46 480 81025.

Received 13 April 2005 ,Revised 8 June 2005 ,Accepted 21 June 2005.

References 

  1. Elkind MS, Sacco RL. Stroke risk factors and stroke prevention. Sem Neurol. 1998;18:429–440
  2. Higashi Y, Oshima T, Sasaki N, et al. Relationship between insulin resistance and endothelium dependent vascular relaxation in patients with essential hypertension. Hypertension. 1997;29:280–285
  3. Miyazaki H, Matsuoka H, Cooke JP. Endogenous nitric oxide synthase inhibitor. A novel marker of atherosclerosis. Circulation. 1999;99:1141–1146
  4. Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997;48:489–509
  5. McAllister RJ, Fickling SA, Whitley GSJ, Vallence . Metabolism of methylarginines by human vasculature: implications for the regulation of nitric oxide synthesis. Br J Pharmacol. 1992;112:43–48
  6. Vallance P, Leone A, Calver A, Collier J, Moncada S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol. 1992;20:S60–S62
  7. Valkonen VP, Päivä H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127–2128
  8. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003;24:1912–1919
  9. Yoo J-H, Lee S-C. Elevated levels of plasma homocysteine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis. 2001;158:425–430
  10. Aho K, Harmsen P, Hatano S, Marquardsen J, Smirnov VE, Strasser T. Cerebrovascular disease in the community: results of a WHO collaboration study. Bull World Health Organ. 1980;58:113–130
  11. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183–97.
  12. Bluth EI, Wetzner SM, Stavros AT, Aufrichtig D, Marish KW, Baker JD. Carotid duplex sonography: a multicenter recommendation for standardized imaging and Doppler criteria. RadioGraphics. 1988;8:487–506Fig. 22
  13. Jeppsson JO, Jerntorp P, Sundkvist G, Englund H, Nylund V. Measurement of hemoglobin A1c by a new liquid-chromatography assay; methodology, clinical utility, and relation to tolerance evaluated. Clin Chem. 1986;32:1867–1872
  14. Teerlink T, Nijveldt RJ, de Jong S, van Leeuwen PAM. Determination of arginine, asymmetric dimethylarginine in human plasma and other biological samples by high-performance liquid chromatography. Anal Biochem. 2002;303:131–137
  15. Böger RH. The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor. Cardiovasc Res. 2003;59:824–833
  16. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994;89:36–44
  17. Lundman P, Eriksson MJ, Stűhlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol. 2001;38:111–116
  18. Stűhlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced hyperhomocysteinemia: role of asymmetric dimethylarginine. Circulation. 2003;108:933–938
  19. Böger RH, Bode-Böger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842–1847
  20. Lin KY, Ito A, Asagami T, et al. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation. 2002;106:987–992
  21. Nijveldt RJ, Teerlink T, Siroen MPC, van Lambalgen AA, Rauwerda JA, van Leeuwen PA. The liver is an important organ in the metabolism of asymmetrical dimethylarginine (ADMA). Clin Nutr. 2003;22:17–20
  22. Abbasi F, Asagmi T, Coke JP, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol. 2001;88:1201–1203
  23. Surdacki A, Nowicki M, Sandmann J. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol. 1999;33:652–658
  24. Böger RH, Bode-Böger SM, Thiele W, Junker W, Alexander K, Frölich JC. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 1997;95:2068–2074
  25. Purroy F, Montaner J, Rovira A, Delgado P, Quintana M, Alvarez-Sabin J. Higher risk of further vascular events among transient ischemic attack patients with diffusion-weighted imaging acute ischemic lesions. Stroke. 2004;35:2313–2319
  26. Chan NN, Chan JC. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?. Diabetologia. 2002;45:1609–1616
  27. Jeserich M, Műnzel T, Just H, Drexler H. Reduced plasma l-arginine in hyper-cholesterolemia. Lancet. 1992;339:561
  28. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rozuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol. 2004;94:157–161

PII: S0021-9150(05)00441-7

doi: 10.1016/j.atherosclerosis.2005.06.033

Atherosclerosis
Volume 185, Issue 2 , Pages 271-277 , April 2006

Article Tools